Ionis Pharmaceuticals (NASDAQ: IONS) — Company Overview, News & Financial Data
Ionis Pharmaceuticals develops RNA-targeted drugs to treat severe diseases, aiming to expand its innovative pipeline for better patient outcomes.
Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company focused on discovering and developing RNA-targeted therapeutics and nucleic acid-based medicines. The company utilizes antisense technology to discover and deliver treatments for patients with serious diseases, with a primary focus on neurology, cardiometabolic disorders, and rare diseases. Ionis advances its pipeline through both independent commercialization and strategic partnerships with global pharmaceutical leaders. Its proprietary platform allows targeted modulation of gene expression, supporting commercial drugs as well as a clinical pipeline of targeted RNA medicines.
Snapshot
Operations
Products and/or services of Ionis Pharmaceuticals
- Commercialized Medicines: Key commercial products including SPINRAZA for spinal muscular atrophy and WAINUA for hereditary transthyretin-mediated amyloidosis, generating significant licensing revenues, milestone payments, and commercial royalties through global marketing partnerships.
- Neurology Therapeutics: Clinical development of targeted antisense oligonucleotides addressing severe neurological and neurodegenerative conditions, including advanced trial programs for amyotrophic lateral sclerosis, Alexander disease, Huntington's disease, and rare pediatric neurodevelopmental disorders.
- Cardiometabolic Programs: Development of RNA-targeted medicines designed to address severe metabolic and cardiovascular conditions, including clinical candidates targeting severe hypertriglyceridemia, familial chylomicronemia syndrome, and key cardiovascular risk factors across broad patient populations.
- Rare Disease Therapeutics: Discovery and clinical evaluation of nucleic acid therapeutics focused on rare genetic disorders, utilizing targeted molecular mechanisms to regulate specific gene expression where limited treatment options exist.
- Antisense Drug Technology Platform: Proprietary platform for designing single-stranded RNA and DNA targeted oligonucleotides, enabling precise molecular targeting to inhibit, restore, or modify protein production associated with underlying disease pathways.
- Partnered Licensing Collaborations: Strategic partnerships and licensing agreements with global pharmaceutical companies to co-develop and commercialize candidate molecules, leveraging partner commercial infrastructure for global clinical execution, regulatory submissions, and commercial distribution.
Ionis Pharmaceuticals executive team
- Dr. Brett P. Monia Ph.D.Founder, CEO & Director
- Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.Executive VP of Finance & CFO
- Mr. Patrick R. O'Neil Esq.Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary
- Mr. Kyle JenneExecutive VP & Chief Global Product Strategy Officer
- Mr. Darren GonzalesChief Accounting Officer & Senior VP
- Dr. C. Frank Bennett BSc, Ph.D.Executive VP & Chief Scientific Officer
- Mr. D. Wade Walke Ph.D.Senior Vice President of Investor Relations
- Ms. Tracy Berns J.D.Senior VP and Chief Compliance & Quality Assurance Officer
- Ms. Hayley SofferVice President of Corporate Communications
- Ms. Shannon L. Devers DeversExecutive VP & Chief Human Resource Officer